The availability of IL-1-targeting agents unveiled the pathophysiological role of IL-1-mediated inflammation in a wide range of disorders beyond the spectrum of CIRDs, including T2D and CVD which are frequent comorbidities in rheumatic patients [154]. Here, IL1B is linked to type 2 diabetes mellitus.